Financial Survey: Assure (NASDAQ:IONM) vs. Neuronetics (NASDAQ:STIM)

Neuronetics (NASDAQ:STIM) and Assure (NASDAQ:IONM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Neuronetics and Assure, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	0	1	3	0	2.75
Assure	0	0	0	0	0.00

Neuronetics currently has a consensus price target of $4.67, suggesting a potential upside of 100.29%. Given Neuronetics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Neuronetics is more favorable than Assure.

Profitability

This table compares Neuronetics and Assure’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neuronetics	-50.09%	-141.24%	-32.77%
Assure	-25,178.32%	N/A	-249.78%

Risk & Volatility

Neuronetics has a beta of 2.11, suggesting that its share price is 111% more volatile than the S&P 500. Comparatively, Assure has a beta of 1.91, suggesting that its share price is 91% more volatile than the S&P 500.

Insider and Institutional Ownership

53.6% of Neuronetics shares are held by institutional investors. Comparatively, 3.3% of Assure shares are held by institutional investors. 9.8% of Neuronetics shares are held by insiders. Comparatively, 3.8% of Assure shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Neuronetics and Assure”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$72.71 million	0.97	-$30.19 million	($1.23)	-1.89
Assure	$149,000.00	0.21	-$26.08 million	N/A	N/A

Assure has lower revenue, but higher earnings than Neuronetics.

Summary

Neuronetics beats Assure on 10 of the 12 factors compared between the two stocks.

About Neuronetics

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

About Assure

Assure Holdings Corp., through its subsidiaries, provides technical and professional intraoperative neuromonitoring surgical support services in the United States. It offers services in the areas of neurosurgery, spine, cardiovascular, orthopedic, ear, nose, throat, and other surgical procedures. The company delivers various clinical and operational services, including scheduling of the interoperative neurophysiologist and supervising practitioner, real time monitoring, patient advocacy, and billing services to support surgeons and medical facilities during invasive procedures. Assure Holdings Corp. is based in Englewood, Colorado.